Company intelligence / Profile preview

Oikos

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Oikos is a biotechnology company focused on developing a new class of biological products for agriculture using RNA interference (RNAi) technology. The company's platform is designed to provide highly specific, environmentally friendly crop protection solutions that target pests and pathogens without affecting non-target organisms. By leveraging the natural mechanism of RNAi, Oikos aims to reduce the reliance on traditional chemical pesticides and promote sustainable farming practices. The company is currently in the pre-clinical stage, advancing its pipeline of RNA-based treatments for various agricultural challenges.

Modalities: RNA therapySmall interfering RNA
Industry: Agriculture & AgTech

Beyond the preview

Go deeper on Oikos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oikos.

Explore the full profile